CJ Bioscience Past Earnings Performance
Past criteria checks 0/6
CJ Bioscience's earnings have been declining at an average annual rate of -39%, while the Healthcare Services industry saw earnings growing at 13.8% annually. Revenues have been growing at an average rate of 1.4% per year.
Key information
-39.0%
Earnings growth rate
-25.7%
EPS growth rate
Healthcare Services Industry Growth | 16.7% |
Revenue growth rate | 1.4% |
Return on equity | -36.0% |
Net Margin | -424.9% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How CJ Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 5,416 | -23,010 | 9,379 | 22,989 |
31 Dec 23 | 5,575 | -22,913 | 9,371 | 22,823 |
30 Sep 23 | 5,607 | -36,744 | 14,022 | 23,898 |
30 Jun 23 | 5,143 | -37,754 | 14,575 | 23,249 |
31 Mar 23 | 4,561 | -36,031 | 13,567 | 20,777 |
31 Dec 22 | 4,075 | -34,913 | 12,970 | 19,186 |
30 Sep 22 | 3,265 | -29,228 | 8,503 | 13,286 |
30 Jun 22 | 3,110 | -23,075 | 6,916 | 9,422 |
31 Mar 22 | 3,821 | -21,962 | 6,752 | 6,853 |
31 Dec 21 | 4,363 | -19,272 | 6,039 | 4,852 |
30 Sep 21 | 5,580 | -14,929 | 6,481 | 4,258 |
30 Jun 21 | 5,790 | -14,528 | 6,584 | 4,114 |
31 Mar 21 | 5,530 | -10,420 | 5,568 | 4,839 |
31 Dec 20 | 5,312 | -8,763 | 5,375 | 4,984 |
30 Sep 20 | 4,707 | -7,808 | 4,794 | 5,229 |
30 Jun 20 | 4,636 | -6,612 | 3,867 | 5,176 |
31 Mar 20 | 4,789 | -4,988 | 3,746 | 3,949 |
31 Dec 19 | 4,783 | -4,346 | 3,465 | 3,399 |
30 Sep 19 | 4,940 | -3,766 | 3,458 | 3,059 |
31 Dec 18 | 3,924 | -3,135 | 3,165 | 2,282 |
31 Dec 17 | 3,673 | -2,363 | 2,243 | 2,122 |
31 Dec 16 | 2,997 | -2,587 | 1,802 | 1,284 |
31 Dec 15 | 2,864 | -1,450 | 1,919 | 1,482 |
31 Dec 14 | 2,865 | -882 | 1,680 | 930 |
Quality Earnings: A311690 is currently unprofitable.
Growing Profit Margin: A311690 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A311690 is unprofitable, and losses have increased over the past 5 years at a rate of 39% per year.
Accelerating Growth: Unable to compare A311690's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A311690 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.2%).
Return on Equity
High ROE: A311690 has a negative Return on Equity (-35.97%), as it is currently unprofitable.